121 related articles for article (PubMed ID: 37279701)
1. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.
Satoki A; Uchida M; Fujiwara M; Uesawa Y; Shimizu T
Oncology; 2022; 100(3):188-194. PubMed ID: 34915520
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2022; 100(7):413-418. PubMed ID: 35504255
[TBL] [Abstract][Full Text] [Related]
4. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database.
Nakao H; Koseki T; Kato K; Yamada S; Tsuboi N; Takahashi K; Mizuno T
J Pharm Pharm Sci; 2023; 26():11453. PubMed ID: 37456806
[No Abstract] [Full Text] [Related]
6. Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database.
Omoto T; Asaka J; Sakai T; Sato F; Goto N; Kudo K
Biol Pharm Bull; 2021; 44(5):627-634. PubMed ID: 33952819
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study.
Kawahara Y; Murata S; Shimizu T; Uesawa Y; Uchida M
In Vivo; 2023; 37(2):955-961. PubMed ID: 36881059
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Life (Basel); 2022 Aug; 12(9):. PubMed ID: 36143391
[TBL] [Abstract][Full Text] [Related]
9. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
[TBL] [Abstract][Full Text] [Related]
10. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
Nagai J; Ishikawa Y
PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
[TBL] [Abstract][Full Text] [Related]
11. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Santini V; Fenaux P; Mufti GJ; Hellström-Lindberg E; Silverman LR; List A; Gore SD; Seymour JF; Backstrom J; Beach CL
Eur J Haematol; 2010 Aug; 85(2):130-8. PubMed ID: 20394651
[TBL] [Abstract][Full Text] [Related]
12. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
13. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
[TBL] [Abstract][Full Text] [Related]
14. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
15. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
16. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.
Perino J; Mottal N; Bohbot Y; Servant V; Berroneau A; Poustis P; Fenaux P; Laribi K; Charbonnier A; Bilion E; Calmettes C; Bégaud B; Pigneux A; Milpied N; Miremont-Salamé G; Théophile H; Dimicoli-Salazar S
Br J Clin Pharmacol; 2020 May; 86(5):991-998. PubMed ID: 31912911
[TBL] [Abstract][Full Text] [Related]
17. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database.
Kanbayashi Y; Uchida M; Kashiwagi M; Akiba H; Shimizu T
Med Oncol; 2022 Sep; 39(12):219. PubMed ID: 36175697
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database.
Uchida M; Nakano K; Fujiwara M; Uesawa Y; Shimizu T
J Clin Pharm Ther; 2022 Aug; 47(8):1173-1180. PubMed ID: 35316861
[TBL] [Abstract][Full Text] [Related]
20. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
Johnson DB; Manouchehri A; Haugh AM; Quach HT; Balko JM; Lebrun-Vignes B; Mammen A; Moslehi JJ; Salem JE
J Immunother Cancer; 2019 May; 7(1):134. PubMed ID: 31118078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]